Cellosaurus logo
expasy logo

Cellosaurus MDA-MB-231/PacR (CVCL_4Z64)

[Text version]
Cell line name MDA-MB-231/PacR
Accession CVCL_4Z64
Resource Identification Initiative To cite this cell line use: MDA-MB-231/PacR (RRID:CVCL_4Z64)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0062 (MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
Publications

CLPUB00286
Sprouse A.A.
Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
Thesis PhD (2014), University of Indiana, United States

PubMed=25275030
Sprouse A.A., Herbert B.-S.
Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
Anticancer Res. 34:5363-5374(2014)

Cross-references
Cell line databases/resources cancercelllines; CVCL_4Z64
Encyclopedic resources Wikidata; Q54904617
Entry history
Entry creation14-Dec-2015
Last entry update05-Oct-2023
Version number18